BioSpace News Archive

IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the commencement of a proposed public offering of its ordinary shares.

BD, a leading global medical technology company, announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 12:45 pm Eastern Time.

Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by Pfizer that the first subject in a Phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532.

Sirnaomics Ltd. announced today the interim results from a Phase I clinical trial evaluating the safety, tolerability and anti-tumor activity of the Company’s siRNA (small interfering RNA) drug candidate, STP707 with intravenous (IV) administration in the United States.

ALT operates under the Industrial Assets business unit and provides surplus strategy services for recovery, refurbishment and resale of assets in the life sciences industry which include lifetime support to its buyers, a price match guarantee, and a white glove service that incorporates installation of equipment purchased and removal of all packaging.

Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO) today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF).

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI) today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will present the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 10:30 a.m. Eastern Time.

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the quarter and fiscal year ended September 30, 2022.

HTG Molecular Diagnostics, Inc. announced that as a result of its one-for-twelve reserve stock split which became effective at 4:15 p.m. Eastern Time on December 20, 2022, its common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market effective with the open of the market tomorrow, Wednesday, December 21, 2022.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) has entered into a royalty interest financing agreement totaling $31 million with HealthCare Royalty (HCRx) for Ebvallo™ in Europe and other territories covered by Atara’s commercialization agreement with Pierre Fabre.